Pfenex Inc.
DelistedCIK 1478121fmd_0B8VXSYTZRP19KVP1A40FV2XEDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2020, 31 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 11 | 12 | 11 | 10 | 60 | 29 | 15 | 50 |
| Cost of revenue | 7 | 6 | 7 | 5 | 5 | 5 | 5 | 5 |
| Gross profit | 4 | 5 | 3 | 5 | 55 | 24 | 10 | 45 |
| Research and development | 2 | 5 | 4 | 18 | 32 | 32 | 34 | 26 |
| Selling, general and administrative | 7 | 7 | 9 | 15 | 17 | 18 | 16 | 19 |
| Total operating expenses | 9 | 12 | 13 | 33 | 50 | 50 | 50 | 45 |
| Operating income | (5) | (7) | (10) | (28) | 5 | (26) | (40) | 1 |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | – | (0) | (0) | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (5) | (7) | (10) | (28) | 5 | (26) | (40) | 1 |
| Income tax expense | (2) | (3) | 0 | 0 | (0) | (0) | 0 | 0 |
| Net income from continuing operations | (3) | (4) | (10) | (28) | 5 | (26) | (40) | 1 |
| Net income | (3) | (4) | (10) | (28) | 5 | (26) | (40) | 1 |
| Net income to common shareholders | (4) | (6) | (10) | (28) | – | – | – | – |